GLP-1 Receptor Agonists May Lower Mortality in IMIDs and T2D
TOPLINE: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for all-cause mortality and major adverse cardiovascular events (MACE) than for dipeptidyl peptidase 4 (DPP-4) inhibitors in patients with immune-mediated …